Bio-Reference Laboratories Inc
Bio-Reference Laboratories — Merger or Acquisition (June 2015)
13 slides from Bio-Reference Laboratories's merger presentation, Jun 18, 2015

Slide 1: General Overview June 2015
General Overview 18 June 2015 Exhibit 99.3

Slide 2: Our Vision: a leading specialty pharmaceutical company
Our Vision We are a leading specialty pharmaceutical company To be the leading developer and supplier of highly potent pharmaceutical products for global markets Click above to view EirGen’s expanded facility

Slide 3: Ireland: Fact Sheet
Ireland: Fact Sheet Waterford Cork Dublin • Population 4.2 million • Largest Exporter of Pharmaceuticals in the World, th largest producer. of World’s Top Pharma Companies Located in Ireland • Home to Pharma companies; pharma and biopharma plants are FDA approved. 25,000 direct & 25,000 indirect emp

Slide 4: Business Overview
Business Overview A Specialty Pharmaceutical Company Focused on the development and commercial supply of highly potent pharmaceutical products In a purpose built, state of the art, high containment facility

Slide 5: Introductions – EirGen Founders
Introductions – EirGen Founders PATSY CARNEY Chief Executive Officer/ Co-Founder » Co-founded EirGen » Previously Head of Operations and BD for IVAX Ireland (14 years) » Holds a BSc In Industrial Chemistry from University of Limerick and an MBA from University of Limerick TOM BRENNAN Chief Technical

Slide 6: EirGen Key Milestones
EirGen Founded EirGen Key Milestones 2005 2006 2008 2009 2011 2012 2013 Successful Regulatory Audit OPEN FOR BUSINESS Submission of First Pan EU EirGen License 1. st License Approval in Canada 2. th Oncology product license submitted to US FDA 3. st commercial product launch in EU 1. Two oncology pr

Slide 7: Current Position: where we are now
Current Position: where we are now » 98 employees, all graduates » 31 successful Clinical Studies » 42 countries for commercial product supply » 27 products in R&D » 10 Products filed with US FDA to date, 3 approved » Pan EU CTD Dossiers filed to date and approved » Oncology Products filed with Japa

Slide 8: Current Position: Regulatory Status
Current Position: Regulatory Status » Global license submission strategy » FDA, Aug 2014, no 483’s » IMB (EMA), May 2015, no major observations » Licensed to handle Cytotoxic Materials

Slide 9: Therapeutic Focus
Therapeutic Focus » Oncology Molecules » Immunosuppressants » Prostaglandins » Cytotoxic Molecules » Hormonals » Steroids

Slide 10: Global Presence
Category Countries Global Presence Commercial (BLUE) Licenses Pending (ORANGE) Customer Contracts (GREEN)

Slide 11: Existing Business Model
EirGen Existing Business Model R&D (non- GMP and GMP) Clinical studies and license approval Routine on- going commercial supply Sales, marketing & distribution Strategic Partner

Slide 12: OPKO Opportunities
EirGen OPKO Opportunities » API Vertical Integration - Synergies with OPKO Finetech, Israel » Product Development & Manufacturing - OPKO’s current & future products » Irish based Supply Chain Hub - global distribution of OPKO Products » Tax efficient R&D Hub - proven R&D track record since incorpora

Slide 13: Thank You
Thank You www.EirGen.com
Source: SEC EDGAR · 425 filed Jun 18, 2015


